- Home
- BWG vs CGEN Comparison
BWG vs CGEN Comparison
Compare BWG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWG
- CGEN
- Stock Information
- Founded
- BWG 2012
- CGEN 1993
- Country
- BWG United States
- CGEN Israel
- Employees
- BWG N/A
- CGEN N/A
- Industry
- BWG Finance/Investors Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BWG Finance
- CGEN Health Care
- Exchange
- BWG Nasdaq
- CGEN Nasdaq
- Market Cap
- BWG 140.2M
- CGEN 135.6M
- IPO Year
- BWG N/A
- CGEN 2000
- Fundamental
- Price
- BWG $7.85
- CGEN $1.47
- Analyst Decision
- BWG
- CGEN Strong Buy
- Analyst Count
- BWG 0
- CGEN 1
- Target Price
- BWG N/A
- CGEN $4.00
- AVG Volume (30 Days)
- BWG 53.8K
- CGEN 268.4K
- Earning Date
- BWG 01-01-0001
- CGEN 05-19-2025
- Dividend Yield
- BWG 11.37%
- CGEN N/A
- EPS Growth
- BWG N/A
- CGEN N/A
- EPS
- BWG N/A
- CGEN N/A
- Revenue
- BWG N/A
- CGEN $27,864,000.00
- Revenue This Year
- BWG N/A
- CGEN $11.81
- Revenue Next Year
- BWG N/A
- CGEN $28.37
- P/E Ratio
- BWG N/A
- CGEN N/A
- Revenue Growth
- BWG N/A
- CGEN N/A
- 52 Week Low
- BWG $6.86
- CGEN $1.13
- 52 Week High
- BWG $8.65
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- BWG 41.77
- CGEN 49.50
- Support Level
- BWG $7.46
- CGEN $1.13
- Resistance Level
- BWG $7.77
- CGEN $1.35
- Average True Range (ATR)
- BWG 0.20
- CGEN 0.11
- MACD
- BWG -0.01
- CGEN 0.03
- Stochastic Oscillator
- BWG 39.00
- CGEN 85.00
About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.